Clinical characteristic N=17
Gender (Females N (%)) 16 (94.1)
Age at disease onset (years, M, (IQR) 31(23-42.5)
Age at SF sampling (years, M, (IQR) 57 (48.5-63.2)
Disease duration (years, M, (IQR) 16 (6-34)
Active smoking at sampling (N (%)) 6 (35.3)
Organ involvement
Lupus Nephritis (N (%)) 3 (17.6)
Cutaneous manifestations (N (%)) 6 (35.3)
Neurolupus (N (%)) 3 (17.6)
Serositis (N (%)) 2 (11.8)
Secondary APS (N (%)) 3 (17.6)
Treatment at sampling
Glucocorticoids (N (%)) 10 (58.8)
Antimalarial (N (%)) 10 (58.8)
Methotrexate (N (%)) 3 (17.6)
Combined therapy# (N (%)) 6 (35.3)
No active treatment (N (%)) 2 (11.8)
Autoantibodies
ANA (N (%)) 17 (100)
anti-dsDNA (N (%)) 6 (35.3)
RF (N (%)) 2 (11.8)
anti-SSA/SSB (N (%)) 4 (23.5)
anti-RNP (N (%)) 3 (17.6)
anti-PL (N (%)) 9 (52.9)